nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—CYP2D6—Hydroxyurea—head and neck cancer	0.166	0.343	CbGbCtD
Citalopram—CYP1A2—Fluorouracil—head and neck cancer	0.0772	0.159	CbGbCtD
Citalopram—ABCB1—Vinblastine—head and neck cancer	0.0625	0.129	CbGbCtD
Citalopram—CYP2D6—Vinblastine—head and neck cancer	0.0589	0.121	CbGbCtD
Citalopram—ABCB1—Docetaxel—head and neck cancer	0.0515	0.106	CbGbCtD
Citalopram—CYP3A4—Vinblastine—head and neck cancer	0.0375	0.0772	CbGbCtD
Citalopram—CYP3A4—Docetaxel—head and neck cancer	0.0309	0.0637	CbGbCtD
Citalopram—Neoplasm—Docetaxel—head and neck cancer	0.00106	0.00242	CcSEcCtD
Citalopram—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00106	0.00241	CcSEcCtD
Citalopram—Lightheadedness—Docetaxel—head and neck cancer	0.00105	0.00239	CcSEcCtD
Citalopram—Muscular weakness—Fluorouracil—head and neck cancer	0.00104	0.00237	CcSEcCtD
Citalopram—Angiopathy—Hydroxyurea—head and neck cancer	0.00103	0.00235	CcSEcCtD
Citalopram—Dysphagia—Fluorouracil—head and neck cancer	0.00102	0.00233	CcSEcCtD
Citalopram—Sepsis—Docetaxel—head and neck cancer	0.00102	0.00232	CcSEcCtD
Citalopram—Chills—Hydroxyurea—head and neck cancer	0.00102	0.00232	CcSEcCtD
Citalopram—Eosinophilia—Fluorouracil—head and neck cancer	0.00101	0.0023	CcSEcCtD
Citalopram—Ill-defined disorder—Vinblastine—head and neck cancer	0.00101	0.00229	CcSEcCtD
Citalopram—Alopecia—Hydroxyurea—head and neck cancer	0.00101	0.00229	CcSEcCtD
Citalopram—Anaemia—Vinblastine—head and neck cancer	0.001	0.00228	CcSEcCtD
Citalopram—Angina pectoris—Fluorouracil—head and neck cancer	0.000997	0.00227	CcSEcCtD
Citalopram—Phlebitis—Docetaxel—head and neck cancer	0.000992	0.00225	CcSEcCtD
Citalopram—Erythema—Hydroxyurea—head and neck cancer	0.000991	0.00225	CcSEcCtD
Citalopram—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000983	0.00223	CcSEcCtD
Citalopram—Malaise—Vinblastine—head and neck cancer	0.00098	0.00223	CcSEcCtD
Citalopram—Vertigo—Vinblastine—head and neck cancer	0.000976	0.00222	CcSEcCtD
Citalopram—Leukopenia—Vinblastine—head and neck cancer	0.000973	0.00221	CcSEcCtD
Citalopram—Pancytopenia—Fluorouracil—head and neck cancer	0.000972	0.00221	CcSEcCtD
Citalopram—Deafness—Docetaxel—head and neck cancer	0.000956	0.00217	CcSEcCtD
Citalopram—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000951	0.00216	CcSEcCtD
Citalopram—Hepatic failure—Docetaxel—head and neck cancer	0.000951	0.00216	CcSEcCtD
Citalopram—Convulsion—Vinblastine—head and neck cancer	0.000941	0.00214	CcSEcCtD
Citalopram—Hypertension—Vinblastine—head and neck cancer	0.000938	0.00213	CcSEcCtD
Citalopram—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000934	0.00212	CcSEcCtD
Citalopram—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000919	0.00209	CcSEcCtD
Citalopram—Pneumonia—Fluorouracil—head and neck cancer	0.000918	0.00209	CcSEcCtD
Citalopram—Anaemia—Hydroxyurea—head and neck cancer	0.000916	0.00208	CcSEcCtD
Citalopram—Discomfort—Vinblastine—head and neck cancer	0.000914	0.00208	CcSEcCtD
Citalopram—Hot flush—Docetaxel—head and neck cancer	0.000914	0.00208	CcSEcCtD
Citalopram—Infestation—Fluorouracil—head and neck cancer	0.000913	0.00207	CcSEcCtD
Citalopram—Infestation NOS—Fluorouracil—head and neck cancer	0.000913	0.00207	CcSEcCtD
Citalopram—Menopausal symptoms—Docetaxel—head and neck cancer	0.000906	0.00206	CcSEcCtD
Citalopram—Visual disturbance—Docetaxel—head and neck cancer	0.000902	0.00205	CcSEcCtD
Citalopram—Atrial fibrillation—Docetaxel—head and neck cancer	0.000902	0.00205	CcSEcCtD
Citalopram—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.0009	0.00204	CcSEcCtD
Citalopram—Myocardial infarction—Fluorouracil—head and neck cancer	0.000895	0.00203	CcSEcCtD
Citalopram—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000895	0.00203	CcSEcCtD
Citalopram—Dermatitis bullous—Docetaxel—head and neck cancer	0.000894	0.00203	CcSEcCtD
Citalopram—Malaise—Hydroxyurea—head and neck cancer	0.000894	0.00203	CcSEcCtD
Citalopram—Stomatitis—Fluorouracil—head and neck cancer	0.00089	0.00202	CcSEcCtD
Citalopram—Conjunctivitis—Fluorouracil—head and neck cancer	0.000887	0.00202	CcSEcCtD
Citalopram—Urinary tract infection—Fluorouracil—head and neck cancer	0.000887	0.00202	CcSEcCtD
Citalopram—Leukopenia—Hydroxyurea—head and neck cancer	0.000887	0.00202	CcSEcCtD
Citalopram—Cardiac failure—Docetaxel—head and neck cancer	0.000876	0.00199	CcSEcCtD
Citalopram—Lethargy—Docetaxel—head and neck cancer	0.000872	0.00198	CcSEcCtD
Citalopram—Thrombocytopenia—Vinblastine—head and neck cancer	0.000868	0.00197	CcSEcCtD
Citalopram—Epistaxis—Fluorouracil—head and neck cancer	0.000861	0.00196	CcSEcCtD
Citalopram—Convulsion—Hydroxyurea—head and neck cancer	0.000859	0.00195	CcSEcCtD
Citalopram—Hyponatraemia—Docetaxel—head and neck cancer	0.000858	0.00195	CcSEcCtD
Citalopram—Sinusitis—Fluorouracil—head and neck cancer	0.000856	0.00195	CcSEcCtD
Citalopram—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000855	0.00194	CcSEcCtD
Citalopram—Pain in extremity—Docetaxel—head and neck cancer	0.000855	0.00194	CcSEcCtD
Citalopram—Agranulocytosis—Fluorouracil—head and neck cancer	0.000852	0.00194	CcSEcCtD
Citalopram—Anorexia—Vinblastine—head and neck cancer	0.000845	0.00192	CcSEcCtD
Citalopram—Migraine—Docetaxel—head and neck cancer	0.000841	0.00191	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000838	0.0019	CcSEcCtD
Citalopram—Discomfort—Hydroxyurea—head and neck cancer	0.000834	0.00189	CcSEcCtD
Citalopram—Haemoglobin—Fluorouracil—head and neck cancer	0.000824	0.00187	CcSEcCtD
Citalopram—Rhinitis—Fluorouracil—head and neck cancer	0.000821	0.00187	CcSEcCtD
Citalopram—Haemorrhage—Fluorouracil—head and neck cancer	0.000819	0.00186	CcSEcCtD
Citalopram—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000815	0.00185	CcSEcCtD
Citalopram—Pharyngitis—Fluorouracil—head and neck cancer	0.000813	0.00185	CcSEcCtD
Citalopram—Oedema—Hydroxyurea—head and neck cancer	0.000809	0.00184	CcSEcCtD
Citalopram—Ataxia—Docetaxel—head and neck cancer	0.000804	0.00183	CcSEcCtD
Citalopram—Infection—Hydroxyurea—head and neck cancer	0.000803	0.00183	CcSEcCtD
Citalopram—Paraesthesia—Vinblastine—head and neck cancer	0.000796	0.00181	CcSEcCtD
Citalopram—Dehydration—Docetaxel—head and neck cancer	0.000795	0.00181	CcSEcCtD
Citalopram—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000793	0.0018	CcSEcCtD
Citalopram—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000792	0.0018	CcSEcCtD
Citalopram—Liver function test abnormal—Docetaxel—head and neck cancer	0.000789	0.00179	CcSEcCtD
Citalopram—Skin disorder—Hydroxyurea—head and neck cancer	0.000786	0.00178	CcSEcCtD
Citalopram—Dry skin—Docetaxel—head and neck cancer	0.000784	0.00178	CcSEcCtD
Citalopram—Orthostatic hypotension—Docetaxel—head and neck cancer	0.000781	0.00177	CcSEcCtD
Citalopram—Abdominal pain upper—Docetaxel—head and neck cancer	0.000781	0.00177	CcSEcCtD
Citalopram—Breast disorder—Docetaxel—head and neck cancer	0.000772	0.00176	CcSEcCtD
Citalopram—Anorexia—Hydroxyurea—head and neck cancer	0.000771	0.00175	CcSEcCtD
Citalopram—Decreased appetite—Vinblastine—head and neck cancer	0.000771	0.00175	CcSEcCtD
Citalopram—Cramp muscle—Docetaxel—head and neck cancer	0.00077	0.00175	CcSEcCtD
Citalopram—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.00077	0.00175	CcSEcCtD
Citalopram—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.00077	0.00175	CcSEcCtD
Citalopram—Nasopharyngitis—Docetaxel—head and neck cancer	0.000764	0.00174	CcSEcCtD
Citalopram—Pain—Vinblastine—head and neck cancer	0.000758	0.00172	CcSEcCtD
Citalopram—Constipation—Vinblastine—head and neck cancer	0.000758	0.00172	CcSEcCtD
Citalopram—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000754	0.00171	CcSEcCtD
Citalopram—Dysphagia—Docetaxel—head and neck cancer	0.000739	0.00168	CcSEcCtD
Citalopram—Arrhythmia—Fluorouracil—head and neck cancer	0.000732	0.00166	CcSEcCtD
Citalopram—Feeling abnormal—Vinblastine—head and neck cancer	0.000731	0.00166	CcSEcCtD
Citalopram—Bronchospasm—Docetaxel—head and neck cancer	0.000727	0.00165	CcSEcCtD
Citalopram—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000725	0.00165	CcSEcCtD
Citalopram—Alopecia—Fluorouracil—head and neck cancer	0.000724	0.00165	CcSEcCtD
Citalopram—Dyspnoea—Hydroxyurea—head and neck cancer	0.000721	0.00164	CcSEcCtD
Citalopram—Angina pectoris—Docetaxel—head and neck cancer	0.00072	0.00164	CcSEcCtD
Citalopram—Somnolence—Hydroxyurea—head and neck cancer	0.000719	0.00163	CcSEcCtD
Citalopram—Erythema—Fluorouracil—head and neck cancer	0.000713	0.00162	CcSEcCtD
Citalopram—Dyspepsia—Hydroxyurea—head and neck cancer	0.000712	0.00162	CcSEcCtD
Citalopram—Decreased appetite—Hydroxyurea—head and neck cancer	0.000703	0.0016	CcSEcCtD
Citalopram—Pancytopenia—Docetaxel—head and neck cancer	0.000702	0.00159	CcSEcCtD
Citalopram—Abdominal pain—Vinblastine—head and neck cancer	0.000701	0.00159	CcSEcCtD
Citalopram—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000698	0.00159	CcSEcCtD
Citalopram—Fatigue—Hydroxyurea—head and neck cancer	0.000697	0.00158	CcSEcCtD
Citalopram—Constipation—Hydroxyurea—head and neck cancer	0.000692	0.00157	CcSEcCtD
Citalopram—Pain—Hydroxyurea—head and neck cancer	0.000692	0.00157	CcSEcCtD
Citalopram—Weight increased—Docetaxel—head and neck cancer	0.000672	0.00153	CcSEcCtD
Citalopram—Vision blurred—Fluorouracil—head and neck cancer	0.000672	0.00153	CcSEcCtD
Citalopram—Weight decreased—Docetaxel—head and neck cancer	0.000668	0.00152	CcSEcCtD
Citalopram—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000666	0.00151	CcSEcCtD
Citalopram—Pneumonia—Docetaxel—head and neck cancer	0.000663	0.00151	CcSEcCtD
Citalopram—Anaemia—Fluorouracil—head and neck cancer	0.000659	0.0015	CcSEcCtD
Citalopram—Infestation NOS—Docetaxel—head and neck cancer	0.000659	0.0015	CcSEcCtD
Citalopram—Infestation—Docetaxel—head and neck cancer	0.000659	0.0015	CcSEcCtD
Citalopram—Hypersensitivity—Vinblastine—head and neck cancer	0.000653	0.00148	CcSEcCtD
Citalopram—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000653	0.00148	CcSEcCtD
Citalopram—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000649	0.00148	CcSEcCtD
Citalopram—Myocardial infarction—Docetaxel—head and neck cancer	0.000646	0.00147	CcSEcCtD
Citalopram—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000646	0.00147	CcSEcCtD
Citalopram—Stomatitis—Docetaxel—head and neck cancer	0.000642	0.00146	CcSEcCtD
Citalopram—Jaundice—Docetaxel—head and neck cancer	0.000642	0.00146	CcSEcCtD
Citalopram—Conjunctivitis—Docetaxel—head and neck cancer	0.00064	0.00145	CcSEcCtD
Citalopram—Body temperature increased—Hydroxyurea—head and neck cancer	0.000639	0.00145	CcSEcCtD
Citalopram—Leukopenia—Fluorouracil—head and neck cancer	0.000638	0.00145	CcSEcCtD
Citalopram—Asthenia—Vinblastine—head and neck cancer	0.000636	0.00145	CcSEcCtD
Citalopram—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000623	0.00142	CcSEcCtD
Citalopram—Epistaxis—Docetaxel—head and neck cancer	0.000621	0.00141	CcSEcCtD
Citalopram—Convulsion—Fluorouracil—head and neck cancer	0.000618	0.0014	CcSEcCtD
Citalopram—Agranulocytosis—Docetaxel—head and neck cancer	0.000615	0.0014	CcSEcCtD
Citalopram—Chest pain—Fluorouracil—head and neck cancer	0.000607	0.00138	CcSEcCtD
Citalopram—Myalgia—Fluorouracil—head and neck cancer	0.000607	0.00138	CcSEcCtD
Citalopram—Diarrhoea—Vinblastine—head and neck cancer	0.000607	0.00138	CcSEcCtD
Citalopram—Discomfort—Fluorouracil—head and neck cancer	0.0006	0.00136	CcSEcCtD
Citalopram—Hypersensitivity—Hydroxyurea—head and neck cancer	0.000596	0.00135	CcSEcCtD
Citalopram—Haemoglobin—Docetaxel—head and neck cancer	0.000594	0.00135	CcSEcCtD
Citalopram—Rhinitis—Docetaxel—head and neck cancer	0.000593	0.00135	CcSEcCtD
Citalopram—Haemorrhage—Docetaxel—head and neck cancer	0.000591	0.00134	CcSEcCtD
Citalopram—Hepatitis—Docetaxel—head and neck cancer	0.000591	0.00134	CcSEcCtD
Citalopram—Hypoaesthesia—Docetaxel—head and neck cancer	0.000588	0.00134	CcSEcCtD
Citalopram—Confusional state—Fluorouracil—head and neck cancer	0.000587	0.00133	CcSEcCtD
Citalopram—Pharyngitis—Docetaxel—head and neck cancer	0.000587	0.00133	CcSEcCtD
Citalopram—Dizziness—Vinblastine—head and neck cancer	0.000586	0.00133	CcSEcCtD
Citalopram—Urinary tract disorder—Docetaxel—head and neck cancer	0.000584	0.00133	CcSEcCtD
Citalopram—Oedema peripheral—Docetaxel—head and neck cancer	0.000583	0.00132	CcSEcCtD
Citalopram—Oedema—Fluorouracil—head and neck cancer	0.000582	0.00132	CcSEcCtD
Citalopram—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000582	0.00132	CcSEcCtD
Citalopram—Connective tissue disorder—Docetaxel—head and neck cancer	0.000581	0.00132	CcSEcCtD
Citalopram—Asthenia—Hydroxyurea—head and neck cancer	0.00058	0.00132	CcSEcCtD
Citalopram—Urethral disorder—Docetaxel—head and neck cancer	0.00058	0.00132	CcSEcCtD
Citalopram—Infection—Fluorouracil—head and neck cancer	0.000578	0.00131	CcSEcCtD
Citalopram—Nervous system disorder—Fluorouracil—head and neck cancer	0.000571	0.0013	CcSEcCtD
Citalopram—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00057	0.0013	CcSEcCtD
Citalopram—Visual impairment—Docetaxel—head and neck cancer	0.00057	0.00129	CcSEcCtD
Citalopram—Tachycardia—Fluorouracil—head and neck cancer	0.000568	0.00129	CcSEcCtD
Citalopram—Vomiting—Vinblastine—head and neck cancer	0.000564	0.00128	CcSEcCtD
Citalopram—Erythema multiforme—Docetaxel—head and neck cancer	0.000559	0.00127	CcSEcCtD
Citalopram—Headache—Vinblastine—head and neck cancer	0.000556	0.00126	CcSEcCtD
Citalopram—Anorexia—Fluorouracil—head and neck cancer	0.000555	0.00126	CcSEcCtD
Citalopram—Diarrhoea—Hydroxyurea—head and neck cancer	0.000553	0.00126	CcSEcCtD
Citalopram—Eye disorder—Docetaxel—head and neck cancer	0.000553	0.00126	CcSEcCtD
Citalopram—Flushing—Docetaxel—head and neck cancer	0.000549	0.00125	CcSEcCtD
Citalopram—Cardiac disorder—Docetaxel—head and neck cancer	0.000549	0.00125	CcSEcCtD
Citalopram—Hypotension—Fluorouracil—head and neck cancer	0.000544	0.00124	CcSEcCtD
Citalopram—Angiopathy—Docetaxel—head and neck cancer	0.000537	0.00122	CcSEcCtD
Citalopram—Dizziness—Hydroxyurea—head and neck cancer	0.000535	0.00122	CcSEcCtD
Citalopram—Immune system disorder—Docetaxel—head and neck cancer	0.000534	0.00121	CcSEcCtD
Citalopram—Mediastinal disorder—Docetaxel—head and neck cancer	0.000533	0.00121	CcSEcCtD
Citalopram—Chills—Docetaxel—head and neck cancer	0.000531	0.00121	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00053	0.00121	CcSEcCtD
Citalopram—Arrhythmia—Docetaxel—head and neck cancer	0.000528	0.0012	CcSEcCtD
Citalopram—Nausea—Vinblastine—head and neck cancer	0.000527	0.0012	CcSEcCtD
Citalopram—Insomnia—Fluorouracil—head and neck cancer	0.000526	0.0012	CcSEcCtD
Citalopram—Paraesthesia—Fluorouracil—head and neck cancer	0.000523	0.00119	CcSEcCtD
Citalopram—Alopecia—Docetaxel—head and neck cancer	0.000523	0.00119	CcSEcCtD
Citalopram—Dyspnoea—Fluorouracil—head and neck cancer	0.000519	0.00118	CcSEcCtD
Citalopram—Mental disorder—Docetaxel—head and neck cancer	0.000518	0.00118	CcSEcCtD
Citalopram—Somnolence—Fluorouracil—head and neck cancer	0.000517	0.00118	CcSEcCtD
Citalopram—Erythema—Docetaxel—head and neck cancer	0.000515	0.00117	CcSEcCtD
Citalopram—Malnutrition—Docetaxel—head and neck cancer	0.000515	0.00117	CcSEcCtD
Citalopram—Vomiting—Hydroxyurea—head and neck cancer	0.000514	0.00117	CcSEcCtD
Citalopram—Dyspepsia—Fluorouracil—head and neck cancer	0.000512	0.00116	CcSEcCtD
Citalopram—Rash—Hydroxyurea—head and neck cancer	0.00051	0.00116	CcSEcCtD
Citalopram—Dermatitis—Hydroxyurea—head and neck cancer	0.000509	0.00116	CcSEcCtD
Citalopram—Headache—Hydroxyurea—head and neck cancer	0.000507	0.00115	CcSEcCtD
Citalopram—Decreased appetite—Fluorouracil—head and neck cancer	0.000506	0.00115	CcSEcCtD
Citalopram—Dysgeusia—Docetaxel—head and neck cancer	0.000504	0.00115	CcSEcCtD
Citalopram—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000503	0.00114	CcSEcCtD
Citalopram—Back pain—Docetaxel—head and neck cancer	0.000498	0.00113	CcSEcCtD
Citalopram—Pain—Fluorouracil—head and neck cancer	0.000498	0.00113	CcSEcCtD
Citalopram—Muscle spasms—Docetaxel—head and neck cancer	0.000495	0.00112	CcSEcCtD
Citalopram—Nausea—Hydroxyurea—head and neck cancer	0.00048	0.00109	CcSEcCtD
Citalopram—Feeling abnormal—Fluorouracil—head and neck cancer	0.00048	0.00109	CcSEcCtD
Citalopram—Anaemia—Docetaxel—head and neck cancer	0.000476	0.00108	CcSEcCtD
Citalopram—Urticaria—Fluorouracil—head and neck cancer	0.000462	0.00105	CcSEcCtD
Citalopram—Syncope—Docetaxel—head and neck cancer	0.000462	0.00105	CcSEcCtD
Citalopram—Leukopenia—Docetaxel—head and neck cancer	0.000461	0.00105	CcSEcCtD
Citalopram—Body temperature increased—Fluorouracil—head and neck cancer	0.00046	0.00105	CcSEcCtD
Citalopram—Palpitations—Docetaxel—head and neck cancer	0.000455	0.00103	CcSEcCtD
Citalopram—Loss of consciousness—Docetaxel—head and neck cancer	0.000452	0.00103	CcSEcCtD
Citalopram—Cough—Docetaxel—head and neck cancer	0.000449	0.00102	CcSEcCtD
Citalopram—Convulsion—Docetaxel—head and neck cancer	0.000446	0.00101	CcSEcCtD
Citalopram—Hypertension—Docetaxel—head and neck cancer	0.000444	0.00101	CcSEcCtD
Citalopram—Chest pain—Docetaxel—head and neck cancer	0.000438	0.000996	CcSEcCtD
Citalopram—Arthralgia—Docetaxel—head and neck cancer	0.000438	0.000996	CcSEcCtD
Citalopram—Myalgia—Docetaxel—head and neck cancer	0.000438	0.000996	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000435	0.000989	CcSEcCtD
Citalopram—Hypersensitivity—Fluorouracil—head and neck cancer	0.000429	0.000974	CcSEcCtD
Citalopram—Dry mouth—Docetaxel—head and neck cancer	0.000429	0.000974	CcSEcCtD
Citalopram—Confusional state—Docetaxel—head and neck cancer	0.000424	0.000963	CcSEcCtD
Citalopram—Oedema—Docetaxel—head and neck cancer	0.00042	0.000955	CcSEcCtD
Citalopram—Anaphylactic shock—Docetaxel—head and neck cancer	0.00042	0.000955	CcSEcCtD
Citalopram—Infection—Docetaxel—head and neck cancer	0.000417	0.000948	CcSEcCtD
Citalopram—Shock—Docetaxel—head and neck cancer	0.000413	0.000939	CcSEcCtD
Citalopram—Nervous system disorder—Docetaxel—head and neck cancer	0.000412	0.000936	CcSEcCtD
Citalopram—Pruritus—Fluorouracil—head and neck cancer	0.000412	0.000936	CcSEcCtD
Citalopram—Thrombocytopenia—Docetaxel—head and neck cancer	0.000411	0.000935	CcSEcCtD
Citalopram—Tachycardia—Docetaxel—head and neck cancer	0.00041	0.000932	CcSEcCtD
Citalopram—Skin disorder—Docetaxel—head and neck cancer	0.000408	0.000927	CcSEcCtD
Citalopram—Anorexia—Docetaxel—head and neck cancer	0.0004	0.00091	CcSEcCtD
Citalopram—Diarrhoea—Fluorouracil—head and neck cancer	0.000398	0.000905	CcSEcCtD
Citalopram—Hypotension—Docetaxel—head and neck cancer	0.000393	0.000892	CcSEcCtD
Citalopram—Dizziness—Fluorouracil—head and neck cancer	0.000385	0.000875	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000383	0.00087	CcSEcCtD
Citalopram—Insomnia—Docetaxel—head and neck cancer	0.00038	0.000863	CcSEcCtD
Citalopram—Paraesthesia—Docetaxel—head and neck cancer	0.000377	0.000857	CcSEcCtD
Citalopram—Dyspnoea—Docetaxel—head and neck cancer	0.000375	0.000851	CcSEcCtD
Citalopram—Somnolence—Docetaxel—head and neck cancer	0.000374	0.000849	CcSEcCtD
Citalopram—Vomiting—Fluorouracil—head and neck cancer	0.00037	0.000841	CcSEcCtD
Citalopram—Dyspepsia—Docetaxel—head and neck cancer	0.00037	0.00084	CcSEcCtD
Citalopram—Rash—Fluorouracil—head and neck cancer	0.000367	0.000834	CcSEcCtD
Citalopram—Dermatitis—Fluorouracil—head and neck cancer	0.000367	0.000833	CcSEcCtD
Citalopram—Decreased appetite—Docetaxel—head and neck cancer	0.000365	0.00083	CcSEcCtD
Citalopram—Headache—Fluorouracil—head and neck cancer	0.000365	0.000829	CcSEcCtD
Citalopram—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000363	0.000824	CcSEcCtD
Citalopram—Fatigue—Docetaxel—head and neck cancer	0.000362	0.000823	CcSEcCtD
Citalopram—Pain—Docetaxel—head and neck cancer	0.000359	0.000816	CcSEcCtD
Citalopram—Constipation—Docetaxel—head and neck cancer	0.000359	0.000816	CcSEcCtD
Citalopram—Feeling abnormal—Docetaxel—head and neck cancer	0.000346	0.000787	CcSEcCtD
Citalopram—Nausea—Fluorouracil—head and neck cancer	0.000346	0.000786	CcSEcCtD
Citalopram—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000344	0.000781	CcSEcCtD
Citalopram—Body temperature increased—Docetaxel—head and neck cancer	0.000332	0.000755	CcSEcCtD
Citalopram—Abdominal pain—Docetaxel—head and neck cancer	0.000332	0.000755	CcSEcCtD
Citalopram—Hypersensitivity—Docetaxel—head and neck cancer	0.00031	0.000703	CcSEcCtD
Citalopram—Asthenia—Docetaxel—head and neck cancer	0.000301	0.000685	CcSEcCtD
Citalopram—Pruritus—Docetaxel—head and neck cancer	0.000297	0.000675	CcSEcCtD
Citalopram—Diarrhoea—Docetaxel—head and neck cancer	0.000287	0.000653	CcSEcCtD
Citalopram—Dizziness—Docetaxel—head and neck cancer	0.000278	0.000631	CcSEcCtD
Citalopram—Vomiting—Docetaxel—head and neck cancer	0.000267	0.000607	CcSEcCtD
Citalopram—Rash—Docetaxel—head and neck cancer	0.000265	0.000602	CcSEcCtD
Citalopram—Dermatitis—Docetaxel—head and neck cancer	0.000265	0.000601	CcSEcCtD
Citalopram—Headache—Docetaxel—head and neck cancer	0.000263	0.000598	CcSEcCtD
Citalopram—Nausea—Docetaxel—head and neck cancer	0.00025	0.000567	CcSEcCtD
Citalopram—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	8.84e-05	0.00118	CbGpPWpGaD
Citalopram—SLC6A3—Transmission across Chemical Synapses—MAPK1—head and neck cancer	8.56e-05	0.00114	CbGpPWpGaD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—MAPK1—head and neck cancer	8.52e-05	0.00114	CbGpPWpGaD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—EGFR—head and neck cancer	8.52e-05	0.00114	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—PTEN—head and neck cancer	8.25e-05	0.0011	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—UROD—head and neck cancer	8e-05	0.00107	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	7.96e-05	0.00106	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	7.73e-05	0.00103	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	7.64e-05	0.00102	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—KISS1—head and neck cancer	7.49e-05	0.001	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	7.4e-05	0.000988	CbGpPWpGaD
Citalopram—CHRM1—Regulation of Actin Cytoskeleton—PIK3CA—head and neck cancer	7.39e-05	0.000987	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	7.35e-05	0.000982	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	7.35e-05	0.000982	CbGpPWpGaD
Citalopram—ABCB1—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	7.33e-05	0.000978	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	7.3e-05	0.000975	CbGpPWpGaD
Citalopram—HTR2C—G alpha (q) signalling events—PIK3CA—head and neck cancer	7.14e-05	0.000953	CbGpPWpGaD
Citalopram—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	7.02e-05	0.000937	CbGpPWpGaD
Citalopram—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	6.92e-05	0.000924	CbGpPWpGaD
Citalopram—SLC6A3—Transmission across Chemical Synapses—HRAS—head and neck cancer	6.88e-05	0.000918	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	6.7e-05	0.000894	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	6.68e-05	0.000891	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	6.57e-05	0.000878	CbGpPWpGaD
Citalopram—SLC6A3—Neuronal System—MAPK1—head and neck cancer	6.56e-05	0.000876	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	6.56e-05	0.000876	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—KISS1—head and neck cancer	6.49e-05	0.000867	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—KISS1—head and neck cancer	6.47e-05	0.000864	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	6.38e-05	0.000852	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	6.37e-05	0.000851	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	6.37e-05	0.000851	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—KISS1—head and neck cancer	6.37e-05	0.00085	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	6.35e-05	0.000848	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	6.35e-05	0.000848	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	6.25e-05	0.000835	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	6.25e-05	0.000835	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	6.23e-05	0.000832	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	6.21e-05	0.000829	CbGpPWpGaD
Citalopram—HRH1—G alpha (q) signalling events—PIK3CA—head and neck cancer	6.18e-05	0.000826	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—UROD—head and neck cancer	6.17e-05	0.000824	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—GRP—head and neck cancer	6.17e-05	0.000823	CbGpPWpGaD
Citalopram—CHRM1—G alpha (q) signalling events—PIK3CA—head and neck cancer	6.16e-05	0.000823	CbGpPWpGaD
Citalopram—ADRA1A—G alpha (q) signalling events—PIK3CA—head and neck cancer	6.07e-05	0.00081	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT6—head and neck cancer	5.99e-05	0.000799	CbGpPWpGaD
Citalopram—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	5.9e-05	0.000788	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NAT2—head and neck cancer	5.64e-05	0.000753	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	5.63e-05	0.000752	CbGpPWpGaD
Citalopram—CHRM1—Circadian rythm related genes—TP53—head and neck cancer	5.63e-05	0.000751	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	5.53e-05	0.000738	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NAT2—head and neck cancer	5.53e-05	0.000738	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	5.51e-05	0.000736	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	5.43e-05	0.000725	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	5.43e-05	0.000725	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—GRP—head and neck cancer	5.34e-05	0.000714	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—GRP—head and neck cancer	5.33e-05	0.000711	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—YAP1—head and neck cancer	5.3e-05	0.000708	CbGpPWpGaD
Citalopram—SLC6A3—Neuronal System—HRAS—head and neck cancer	5.27e-05	0.000703	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—GRP—head and neck cancer	5.24e-05	0.0007	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT6—head and neck cancer	5.19e-05	0.000693	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT6—head and neck cancer	5.17e-05	0.000691	CbGpPWpGaD
Citalopram—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	5.12e-05	0.000683	CbGpPWpGaD
Citalopram—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	5.1e-05	0.000681	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT6—head and neck cancer	5.09e-05	0.00068	CbGpPWpGaD
Citalopram—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	5.02e-05	0.00067	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—DPYD—head and neck cancer	4.95e-05	0.00066	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—head and neck cancer	4.91e-05	0.000655	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—DPYD—head and neck cancer	4.84e-05	0.000647	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—YAP1—head and neck cancer	4.69e-05	0.000627	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	4.64e-05	0.00062	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—YAP1—head and neck cancer	4.6e-05	0.000614	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—YAP1—head and neck cancer	4.59e-05	0.000613	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—YAP1—head and neck cancer	4.58e-05	0.000611	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	4.53e-05	0.000604	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—YAP1—head and neck cancer	4.51e-05	0.000602	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	4.48e-05	0.000598	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	4.42e-05	0.00059	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	4.42e-05	0.00059	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NAT2—head and neck cancer	4.26e-05	0.000569	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NAT2—head and neck cancer	4.16e-05	0.000556	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NAT2—head and neck cancer	3.92e-05	0.000523	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	3.83e-05	0.000512	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—DPYD—head and neck cancer	3.74e-05	0.000499	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	3.71e-05	0.000495	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—DPYD—head and neck cancer	3.65e-05	0.000487	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—YAP1—head and neck cancer	3.55e-05	0.000474	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.53e-05	0.000471	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.49e-05	0.000466	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—YAP1—head and neck cancer	3.46e-05	0.000462	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—DPYD—head and neck cancer	3.44e-05	0.000459	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NAT2—head and neck cancer	3.32e-05	0.000443	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—YAP1—head and neck cancer	3.26e-05	0.000436	CbGpPWpGaD
Citalopram—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	3.13e-05	0.000418	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—IL2—head and neck cancer	3.06e-05	0.000409	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—DPYD—head and neck cancer	2.91e-05	0.000389	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—TYMS—head and neck cancer	2.82e-05	0.000376	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GSTM1—head and neck cancer	2.79e-05	0.000372	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL2—head and neck cancer	2.78e-05	0.000371	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—YAP1—head and neck cancer	2.76e-05	0.000369	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—TYMS—head and neck cancer	2.76e-05	0.000369	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GSTM1—head and neck cancer	2.73e-05	0.000364	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—GPX1—head and neck cancer	2.67e-05	0.000356	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.67e-05	0.000356	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—IL2—head and neck cancer	2.65e-05	0.000354	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—IL2—head and neck cancer	2.65e-05	0.000353	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CYP1A1—head and neck cancer	2.64e-05	0.000353	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—GPX1—head and neck cancer	2.61e-05	0.000349	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—IL2—head and neck cancer	2.61e-05	0.000348	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CYP1A1—head and neck cancer	2.59e-05	0.000345	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NAT2—head and neck cancer	2.56e-05	0.000342	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL2—head and neck cancer	2.41e-05	0.000322	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL2—head and neck cancer	2.4e-05	0.000321	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NOTCH1—head and neck cancer	2.39e-05	0.000319	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL2—head and neck cancer	2.37e-05	0.000316	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2.32e-05	0.00031	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—DPYD—head and neck cancer	2.25e-05	0.0003	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—MAPK3—head and neck cancer	2.24e-05	0.000299	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—YAP1—head and neck cancer	2.13e-05	0.000285	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—TYMS—head and neck cancer	2.13e-05	0.000284	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—MAPK1—head and neck cancer	2.13e-05	0.000284	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—EGFR—head and neck cancer	2.13e-05	0.000284	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTM1—head and neck cancer	2.11e-05	0.000281	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—TYMS—head and neck cancer	2.08e-05	0.000278	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.08e-05	0.000277	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOTCH1—head and neck cancer	2.07e-05	0.000276	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOTCH1—head and neck cancer	2.06e-05	0.000275	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTM1—head and neck cancer	2.05e-05	0.000274	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—PIK3CA—head and neck cancer	2.03e-05	0.000272	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOTCH1—head and neck cancer	2.03e-05	0.000271	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GPX1—head and neck cancer	2.02e-05	0.000269	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CYP1A1—head and neck cancer	2e-05	0.000266	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GPX1—head and neck cancer	1.97e-05	0.000263	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—TYMS—head and neck cancer	1.96e-05	0.000262	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CYP1A1—head and neck cancer	1.95e-05	0.00026	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK3—head and neck cancer	1.94e-05	0.000259	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTM1—head and neck cancer	1.94e-05	0.000259	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK3—head and neck cancer	1.93e-05	0.000258	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK3—head and neck cancer	1.9e-05	0.000254	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GPX1—head and neck cancer	1.85e-05	0.000248	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	1.85e-05	0.000247	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK1—head and neck cancer	1.84e-05	0.000246	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—EGFR—head and neck cancer	1.84e-05	0.000246	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK1—head and neck cancer	1.84e-05	0.000245	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—EGFR—head and neck cancer	1.84e-05	0.000245	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.84e-05	0.000245	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.81e-05	0.000242	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK1—head and neck cancer	1.81e-05	0.000242	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—EGFR—head and neck cancer	1.81e-05	0.000242	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.76e-05	0.000235	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.76e-05	0.000235	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.73e-05	0.000231	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	1.71e-05	0.000228	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	1.66e-05	0.000222	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—TYMS—head and neck cancer	1.66e-05	0.000222	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL2—head and neck cancer	1.64e-05	0.000219	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.64e-05	0.000219	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.64e-05	0.000219	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCND1—head and neck cancer	1.6e-05	0.000214	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—PIK3CA—head and neck cancer	1.6e-05	0.000214	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—PIK3CA—head and neck cancer	1.6e-05	0.000213	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GPX1—head and neck cancer	1.57e-05	0.00021	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—head and neck cancer	1.57e-05	0.00021	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—PIK3CA—head and neck cancer	1.57e-05	0.00021	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.56e-05	0.000208	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.55e-05	0.000206	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—head and neck cancer	1.54e-05	0.000205	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.51e-05	0.000201	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—HRAS—head and neck cancer	1.48e-05	0.000198	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—HRAS—head and neck cancer	1.48e-05	0.000197	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	1.45e-05	0.000194	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—head and neck cancer	1.44e-05	0.000192	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—head and neck cancer	1.43e-05	0.000192	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL2—head and neck cancer	1.42e-05	0.00019	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL2—head and neck cancer	1.42e-05	0.00019	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	1.41e-05	0.000189	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL2—head and neck cancer	1.4e-05	0.000187	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.4e-05	0.000186	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCND1—head and neck cancer	1.39e-05	0.000185	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCND1—head and neck cancer	1.38e-05	0.000185	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.38e-05	0.000185	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTEN—head and neck cancer	1.37e-05	0.000183	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	1.36e-05	0.000182	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTEN—head and neck cancer	1.34e-05	0.000179	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PTEN—head and neck cancer	1.34e-05	0.000179	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PTEN—head and neck cancer	1.34e-05	0.000178	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	1.32e-05	0.000176	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	1.31e-05	0.000176	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—head and neck cancer	1.31e-05	0.000175	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—head and neck cancer	1.3e-05	0.000174	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	1.28e-05	0.000171	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—TYMS—head and neck cancer	1.28e-05	0.000171	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.28e-05	0.000171	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.27e-05	0.000169	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	1.26e-05	0.000168	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—EGFR—head and neck cancer	1.26e-05	0.000168	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GPX1—head and neck cancer	1.21e-05	0.000162	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—head and neck cancer	1.21e-05	0.000162	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—head and neck cancer	1.21e-05	0.000161	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.2e-05	0.00016	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—head and neck cancer	1.2e-05	0.00016	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—head and neck cancer	1.19e-05	0.000159	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	1.19e-05	0.000159	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—head and neck cancer	1.19e-05	0.000158	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	1.18e-05	0.000157	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—head and neck cancer	1.16e-05	0.000155	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK3—head and neck cancer	1.14e-05	0.000153	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK3—head and neck cancer	1.14e-05	0.000152	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	1.12e-05	0.00015	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—head and neck cancer	1.09e-05	0.000146	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	1.09e-05	0.000146	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK1—head and neck cancer	1.09e-05	0.000145	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—EGFR—head and neck cancer	1.09e-05	0.000145	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK1—head and neck cancer	1.09e-05	0.000145	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—EGFR—head and neck cancer	1.09e-05	0.000145	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	1.07e-05	0.000143	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	1.07e-05	0.000143	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TP53—head and neck cancer	1.06e-05	0.000141	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTEN—head and neck cancer	1.04e-05	0.000138	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTEN—head and neck cancer	1.01e-05	0.000135	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—HRAS—head and neck cancer	1.01e-05	0.000135	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CA—head and neck cancer	9.66e-06	0.000129	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTEN—head and neck cancer	9.52e-06	0.000127	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CA—head and neck cancer	9.46e-06	0.000126	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CA—head and neck cancer	9.45e-06	0.000126	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CA—head and neck cancer	9.42e-06	0.000126	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	9.28e-06	0.000124	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—head and neck cancer	9.25e-06	0.000123	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TP53—head and neck cancer	9.14e-06	0.000122	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TP53—head and neck cancer	9.12e-06	0.000122	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TP53—head and neck cancer	8.97e-06	0.00012	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—head and neck cancer	8.91e-06	0.000119	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—HRAS—head and neck cancer	8.75e-06	0.000117	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—HRAS—head and neck cancer	8.72e-06	0.000116	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	8.58e-06	0.000115	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTEN—head and neck cancer	8.07e-06	0.000108	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—head and neck cancer	7.89e-06	0.000105	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—head and neck cancer	7.73e-06	0.000103	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—head and neck cancer	7.72e-06	0.000103	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—head and neck cancer	7.7e-06	0.000103	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	7.58e-06	0.000101	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CA—head and neck cancer	7.3e-06	9.75e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—head and neck cancer	7.14e-06	9.53e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CA—head and neck cancer	7.13e-06	9.52e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CA—head and neck cancer	6.72e-06	8.97e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTEN—head and neck cancer	6.22e-06	8.31e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—head and neck cancer	5.97e-06	7.96e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—head and neck cancer	5.82e-06	7.77e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CA—head and neck cancer	5.69e-06	7.6e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—head and neck cancer	5.49e-06	7.33e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—head and neck cancer	4.65e-06	6.21e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CA—head and neck cancer	4.39e-06	5.86e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—head and neck cancer	3.59e-06	4.79e-05	CbGpPWpGaD
